Hemostemix Inc.
HEM
Hisse Senetlerindeki Sıralama
#32560
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Hisse Fiyatı
$0.04268108
Son senkronizasyon: 2026-10-21
Piyasa Değeri
$9.02M
Değişim (1 gün)
5.73%
Değişim (1 yıl)
-42.09%
Ülke
CA
Ticaret Hemostemix Inc. (HEM)
Kategori
Healthcare
Hemostemix Inc. (HEM) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $0.04 - 2026-10-01
Gün sonu en düşük fiyat: $0.00 - 2005-11-01
Gün sonu en düşük fiyat: $0.00 - 2005-11-01
Hemostemix Inc. için hisse fiyatı geçmişi: 2005 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $765.49 | 8.80% |
CH
|
